• 1
    Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005;2:18.
  • 2
    Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005;59:2915.
  • 3
    Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag 2009;5:25786.
  • 4
    Office of the Information Commissioner of Canada. Information request (ATI 2013-00282) under the Access to Information Act.2013.
  • 5
    Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001;6:8091.
  • 6
    Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:53948.
  • 7
    Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147 Suppl:S16371.
  • 8
    Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001;63:569611.
  • 9
    Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694701.
  • 10
    Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend 2009;103:10713.
  • 11
    Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770804.
  • 12
    Cascini F, Aiello C, Di Tanna G. Increasing Δ-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012;5:3240.
  • 13
    Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:65790.
  • 14
    Goldenberg DL, Clauw DJ, Fitzcharles MA. New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum 2011;41:31934.
  • 15
    Fitzcharles MA, McDougall J, Ste-Marie PA, Padjen I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? [review].Arthritis Rheum 2012;64:241725.
  • 16
    Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken) 2012;64:12028.
  • 17
    Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 2011;72:73544.
  • 18
    Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110:60410.
  • 19
    Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:16473.
  • 20
    Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:502.
  • 21
    Mensinga TT, de Vries I, Kruidenier M, Hunault CC, van den Hengel-Koot IS, Fijen JW, et al. A double-blind, randomized, placebo-controlled, cross-over study on the pharmacokinetics and effects of cannabis.2006. URL:
  • 22
    Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
  • 23
    Legrand SA, Isalberti C, der Linden TV, Bernhoft IM, Hels T, Simonsen KW, et al. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test Anal 2013;5:15665.
  • 24
    Canada Department of Justice, Acts, Regulations, and Health. Marihuana medical access regulations.2001. URL:
  • 25
    Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty?Int J Cardiol 2007;118:1414.
  • 26
    Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974;291:657.
  • 27
    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:28059.
  • 28
    Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:84963.
  • 29
    Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology 2009;206:53149.
  • 30
    Harder VS, Morral AR, Arkes J. Marijuana use and depression among adults: testing for causal associations. Addiction 2006;101:146372.
  • 31
    Van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend 2013;133:3529.
  • 32
    Taylor DR, Hall W. Respiratory health effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand. Intern Med J 2003;33:3103.
  • 33
    Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008;31:2806.
  • 34
    Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 2013;24:181120.
  • 35
    Kondrad E, Reid A. Colorado family physicians' attitudes toward medical marijuana. J Am Board Fam Med 2013;26:5260.
  • 36
    Fletcher J. Marijuana is not a prescription medicine [editorial].CMAJ 2013;185:369.
  • 37
    Fitzcharles M, Ste-Marie PA, Clauw DJ, Jamal S, Karsh J, LeClercq S, et al. Rheumatologists lack confidence in knowledge of cannabinoids in the management of rheumatic conditions: a needs assessment of Canadian rheumatologists [abstract].Arthritis Rheum 2013;65 Suppl:S49.